Selected research
Market Structure
Global Prophylactic Gamma Globulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Prophylactic Gamma Globulin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Prophylactic Gamma Globulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Prophylactic Gamma Globulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Prophylactic Gamma Globulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Prophylactic Gamma Globulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Prophylactic Gamma Globulin include CNBG, Takeda, Shenzhen Weiguang Biological, Beijing Tiantan Biological, CBPO, Sichuan Yuanda Shuyang, Shanghai RAAS, Pacific Shuanglin Bio-pharmacy and Grifols, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Prophylactic Gamma Globulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Prophylactic Gamma Globulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Prophylactic Gamma Globulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prophylactic Gamma Globulin market size, projected growth trends, production technologies, key applications, and end-use industries.
Prophylactic Gamma Globulin Segment by Company
CNBG
Takeda
Shenzhen Weiguang Biological
Beijing Tiantan Biological
CBPO
Sichuan Yuanda Shuyang
Shanghai RAAS
Pacific Shuanglin Bio-pharmacy
Grifols
Hualan Biological
Beijing Bohui Innovation Biotechnology
Baxter
Octapharma
LFB Group
Kedrion Biopharma
BPL
Biotest
ADMA Biologics
Prophylactic Gamma Globulin Segment by Type
IVIg Liquid
IVIg Powder
Prophylactic Gamma Globulin Segment by Application
Autoimmune Disease
Immunodeficiency
Acute Infection
Prophylactic Gamma Globulin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic Gamma Globulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prophylactic Gamma Globulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic Gamma Globulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Prophylactic Gamma Globulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prophylactic Gamma Globulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Prophylactic Gamma Globulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Prophylactic Gamma Globulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- IVIg Liquid
- IVIg Powder
Applications
- Autoimmune Disease
- Immunodeficiency
- Acute Infection
Companies covered
- CNBG
- Takeda
- Shenzhen Weiguang Biological
- Beijing Tiantan Biological
- CBPO
- Sichuan Yuanda Shuyang
- Shanghai RAAS
- Pacific Shuanglin Bio-pharmacy
- Grifols
- Hualan Biological
- Beijing Bohui Innovation Biotechnology
- Baxter
- Octapharma
- LFB Group
- Kedrion Biopharma
- BPL
- Biotest
- ADMA Biologics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Prophylactic Gamma Globulin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Prophylactic Gamma Globulin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Prophylactic Gamma Globulin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Prophylactic Gamma Globulin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Prophylactic Gamma Globulin Market Dynamics
- 2.1 Prophylactic Gamma Globulin Industry Trends
- 2.2 Prophylactic Gamma Globulin Industry Drivers
- 2.3 Prophylactic Gamma Globulin Industry Opportunities and Challenges
- 2.4 Prophylactic Gamma Globulin Industry Restraints
3 Prophylactic Gamma Globulin Market by Manufacturers
- 3.1 Global Prophylactic Gamma Globulin Revenue by Manufacturers (2021-2026)
- 3.2 Global Prophylactic Gamma Globulin Sales by Manufacturers (2021-2026)
- 3.3 Global Prophylactic Gamma Globulin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Prophylactic Gamma Globulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Prophylactic Gamma Globulin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Prophylactic Gamma Globulin Manufacturers, Product Type & Application
- 3.7 Global Prophylactic Gamma Globulin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Prophylactic Gamma Globulin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Prophylactic Gamma Globulin Players Market Share by Revenue in 2025
- 3.8.3 2025 Prophylactic Gamma Globulin Tier 1, Tier 2, and Tier 3
4 Prophylactic Gamma Globulin Market by Type
- 4.1 Prophylactic Gamma Globulin Type Introduction
- 4.1.1 IVIg Liquid
- 4.1.2 IVIg Powder
- 4.2 Global Prophylactic Gamma Globulin Sales by Type
- 4.2.1 Global Prophylactic Gamma Globulin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Prophylactic Gamma Globulin Sales by Type (2021-2032)
- 4.2.3 Global Prophylactic Gamma Globulin Sales Market Share by Type (2021-2032)
- 4.3 Global Prophylactic Gamma Globulin Revenue by Type
- 4.3.1 Global Prophylactic Gamma Globulin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Prophylactic Gamma Globulin Revenue by Type (2021-2032)
- 4.3.3 Global Prophylactic Gamma Globulin Revenue Market Share by Type (2021-2032)
5 Prophylactic Gamma Globulin Market by Application
- 5.1 Prophylactic Gamma Globulin Application Introduction
- 5.1.1 Autoimmune Disease
- 5.1.2 Immunodeficiency
- 5.1.3 Acute Infection
- 5.2 Global Prophylactic Gamma Globulin Sales by Application
- 5.2.1 Global Prophylactic Gamma Globulin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Prophylactic Gamma Globulin Sales by Application (2021-2032)
- 5.2.3 Global Prophylactic Gamma Globulin Sales Market Share by Application (2021-2032)
- 5.3 Global Prophylactic Gamma Globulin Revenue by Application
- 5.3.1 Global Prophylactic Gamma Globulin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Prophylactic Gamma Globulin Revenue by Application (2021-2032)
- 5.3.3 Global Prophylactic Gamma Globulin Revenue Market Share by Application (2021-2032)
6 Global Prophylactic Gamma Globulin Sales by Region
- 6.1 Global Prophylactic Gamma Globulin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Prophylactic Gamma Globulin Sales by Region (2021-2032)
- 6.2.1 Global Prophylactic Gamma Globulin Sales by Region (2021-2026)
- 6.2.2 Global Prophylactic Gamma Globulin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Prophylactic Gamma Globulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Prophylactic Gamma Globulin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Prophylactic Gamma Globulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Prophylactic Gamma Globulin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Prophylactic Gamma Globulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Prophylactic Gamma Globulin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Prophylactic Gamma Globulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Prophylactic Gamma Globulin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Prophylactic Gamma Globulin Revenue by Region
- 7.1 Global Prophylactic Gamma Globulin Revenue by Region
- 7.1.1 Global Prophylactic Gamma Globulin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Prophylactic Gamma Globulin Revenue by Region (2021-2026)
- 7.1.3 Global Prophylactic Gamma Globulin Revenue by Region (2027-2032)
- 7.1.4 Global Prophylactic Gamma Globulin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Prophylactic Gamma Globulin Revenue (2021-2032)
- 7.2.2 North America Prophylactic Gamma Globulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Prophylactic Gamma Globulin Revenue (2021-2032)
- 7.3.2 Europe Prophylactic Gamma Globulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Prophylactic Gamma Globulin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Prophylactic Gamma Globulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Prophylactic Gamma Globulin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Prophylactic Gamma Globulin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CNBG
- 8.1.1 CNBG Company Information
- 8.1.2 CNBG Business Overview
- 8.1.3 CNBG Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CNBG Prophylactic Gamma Globulin Product Portfolio
- 8.1.5 CNBG Recent Developments
- 8.2 Takeda
- 8.2.1 Takeda Company Information
- 8.2.2 Takeda Business Overview
- 8.2.3 Takeda Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Takeda Prophylactic Gamma Globulin Product Portfolio
- 8.2.5 Takeda Recent Developments
- 8.3 Shenzhen Weiguang Biological
- 8.3.1 Shenzhen Weiguang Biological Company Information
- 8.3.2 Shenzhen Weiguang Biological Business Overview
- 8.3.3 Shenzhen Weiguang Biological Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Shenzhen Weiguang Biological Prophylactic Gamma Globulin Product Portfolio
- 8.3.5 Shenzhen Weiguang Biological Recent Developments
- 8.4 Beijing Tiantan Biological
- 8.4.1 Beijing Tiantan Biological Company Information
- 8.4.2 Beijing Tiantan Biological Business Overview
- 8.4.3 Beijing Tiantan Biological Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Beijing Tiantan Biological Prophylactic Gamma Globulin Product Portfolio
- 8.4.5 Beijing Tiantan Biological Recent Developments
- 8.5 CBPO
- 8.5.1 CBPO Company Information
- 8.5.2 CBPO Business Overview
- 8.5.3 CBPO Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 CBPO Prophylactic Gamma Globulin Product Portfolio
- 8.5.5 CBPO Recent Developments
- 8.6 Sichuan Yuanda Shuyang
- 8.6.1 Sichuan Yuanda Shuyang Company Information
- 8.6.2 Sichuan Yuanda Shuyang Business Overview
- 8.6.3 Sichuan Yuanda Shuyang Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Sichuan Yuanda Shuyang Prophylactic Gamma Globulin Product Portfolio
- 8.6.5 Sichuan Yuanda Shuyang Recent Developments
- 8.7 Shanghai RAAS
- 8.7.1 Shanghai RAAS Company Information
- 8.7.2 Shanghai RAAS Business Overview
- 8.7.3 Shanghai RAAS Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Shanghai RAAS Prophylactic Gamma Globulin Product Portfolio
- 8.7.5 Shanghai RAAS Recent Developments
- 8.8 Pacific Shuanglin Bio-pharmacy
- 8.8.1 Pacific Shuanglin Bio-pharmacy Company Information
- 8.8.2 Pacific Shuanglin Bio-pharmacy Business Overview
- 8.8.3 Pacific Shuanglin Bio-pharmacy Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pacific Shuanglin Bio-pharmacy Prophylactic Gamma Globulin Product Portfolio
- 8.8.5 Pacific Shuanglin Bio-pharmacy Recent Developments
- 8.9 Grifols
- 8.9.1 Grifols Company Information
- 8.9.2 Grifols Business Overview
- 8.9.3 Grifols Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Grifols Prophylactic Gamma Globulin Product Portfolio
- 8.9.5 Grifols Recent Developments
- 8.10 Hualan Biological
- 8.10.1 Hualan Biological Company Information
- 8.10.2 Hualan Biological Business Overview
- 8.10.3 Hualan Biological Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Hualan Biological Prophylactic Gamma Globulin Product Portfolio
- 8.10.5 Hualan Biological Recent Developments
- 8.11 Beijing Bohui Innovation Biotechnology
- 8.11.1 Beijing Bohui Innovation Biotechnology Company Information
- 8.11.2 Beijing Bohui Innovation Biotechnology Business Overview
- 8.11.3 Beijing Bohui Innovation Biotechnology Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Beijing Bohui Innovation Biotechnology Prophylactic Gamma Globulin Product Portfolio
- 8.11.5 Beijing Bohui Innovation Biotechnology Recent Developments
- 8.12 Baxter
- 8.12.1 Baxter Company Information
- 8.12.2 Baxter Business Overview
- 8.12.3 Baxter Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Baxter Prophylactic Gamma Globulin Product Portfolio
- 8.12.5 Baxter Recent Developments
- 8.13 Octapharma
- 8.13.1 Octapharma Company Information
- 8.13.2 Octapharma Business Overview
- 8.13.3 Octapharma Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Octapharma Prophylactic Gamma Globulin Product Portfolio
- 8.13.5 Octapharma Recent Developments
- 8.14 LFB Group
- 8.14.1 LFB Group Company Information
- 8.14.2 LFB Group Business Overview
- 8.14.3 LFB Group Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 LFB Group Prophylactic Gamma Globulin Product Portfolio
- 8.14.5 LFB Group Recent Developments
- 8.15 Kedrion Biopharma
- 8.15.1 Kedrion Biopharma Company Information
- 8.15.2 Kedrion Biopharma Business Overview
- 8.15.3 Kedrion Biopharma Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Kedrion Biopharma Prophylactic Gamma Globulin Product Portfolio
- 8.15.5 Kedrion Biopharma Recent Developments
- 8.16 BPL
- 8.16.1 BPL Company Information
- 8.16.2 BPL Business Overview
- 8.16.3 BPL Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 BPL Prophylactic Gamma Globulin Product Portfolio
- 8.16.5 BPL Recent Developments
- 8.17 Biotest
- 8.17.1 Biotest Company Information
- 8.17.2 Biotest Business Overview
- 8.17.3 Biotest Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Biotest Prophylactic Gamma Globulin Product Portfolio
- 8.17.5 Biotest Recent Developments
- 8.18 ADMA Biologics
- 8.18.1 ADMA Biologics Company Information
- 8.18.2 ADMA Biologics Business Overview
- 8.18.3 ADMA Biologics Prophylactic Gamma Globulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 ADMA Biologics Prophylactic Gamma Globulin Product Portfolio
- 8.18.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Prophylactic Gamma Globulin Value Chain Analysis
- 9.1.1 Prophylactic Gamma Globulin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Prophylactic Gamma Globulin Production Mode & Process
- 9.2 Prophylactic Gamma Globulin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Prophylactic Gamma Globulin Distributors
- 9.2.3 Prophylactic Gamma Globulin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst